We have used cDNAs coding for novel
ADP-ribosylation factor-like molecules (ARL184 and ARL184Delta) to alter 19-9
antigen glycoprotein secretion in cultured human
colorectal carcinoma cells SW1116 by transfection and cloning. This ARL contains a lipophilic N-terminal with an isoleucyl and 3 leucyl residues, 4 functioning consensus sequence
GTP binding sites, and 184 total aminoacyl residues. An ARL
cDNA was also constructed deleting the
codon for the N-terminal glycyl moiety. The resulting cell clones were shown by Northern blots to overexpress ARL
mRNA. Electron microscopy-immunocytochemistry also indicated the overexpression of ARL granules subcellularly. Secretion of the
tumor-associated 19-9
antigen into apical medium was decreased 3- to 5-fold and the secretion of TCA/PTA precipitable 3H-labeled
glycoprotein was decreased by 34% in clone SW1116(ARL184)Delta. Western blot analyses of cell homogenates and media were in agreement with the secretion assays and showed a diminution of 170-200 kDa, 19-9, antigenicity in transfected cells and their media. Apical secretion of 19-9
antigen was diminished 14-fold in cells, SW1116 (ARL184)alpha, transfected with the complete ARL
cDNA sequence, suggesting that the glycyl moiety may be required for maximal abatement. However, incorporation of label from [3H]
myristate into 22-kDa bands of
NP-40 extracts and ARL-antigenic molecules of parent cells was 3-fold greater than that in samples from the two transfectants; thus the transfected cells may not myristylate the overexpressed ARL efficiently. Notwithstanding the N-terminal glycyl moiety undergoing some other modification, we conclude that overexpression of this ARL is sufficient to generate a 19-9-deficient phenotype. These ARLs may eventually disrupt terminal
oligosaccharide glycosylation, resulting in an apparent diminished exocytosis of 19-9
glycoprotein carriers by transfected and cloned cells.